Rare Childhood Epilepsies: Dravet Syndrome and Lennox-Gastaut Syndrome

Elizabeth Thiele, MD, PhD, and Elaine C. Wirrell, MD, discuss the commonality of childhood epilepsies, as well as the differences between Dravet syndrome and Lennox-Gastaut syndrome.

Drs Thiele and Wirrell explain how clinicians diagnose patients with Dravet or Lennox-Gastaut syndromes and the typical triggers patients will exhibit.

Two experts detail the current treatment options for Dravet and Lennox-Gastaut syndromes and how they select which patients should use a specific drug.

Elizabeth Thiele, MD, PhD, and Elaine C. Wirrell, MD, discuss the FDA approval of cannabidiol as an oral solution for the treatment of seizures, specifically for both Dravet and Lennox-Gastaut syndromes.

Drs Thiele and Wirrell continue analyzing the benefits of cannabidiol as a therapeutic option for patients with Dravet or Lennox-Gastaut syndromes.

Two experts explain the impact of the drug fenfluramine’s FDA approval in the treatment of Dravet syndrome.

Drs Thiele and Wirrell discuss the benefits of 3 drugs being approved to treat Dravet and Lennox-Gastaut syndromes: cannabidiol, fenfluramine, and the combination of stiripentol and clobazam.

Two experts list new therapies being developed for the treatment of Dravet and Lennox-Gastaut syndromes.

Elizabeth Thiele, MD, PhD, and Elaine C. Wirrell, MD, explain how community neurologists can work with academic center to treat patients with Dravet or Lennox-Gastaut syndromes.